A Study With GLPG1972 in Osteoarthritis Subjects
2017年11月21日 更新者：Galapagos NV
Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Doses of GLPG1972 for 4 Weeks in Subjects With Osteoarthritis
This is a randomized, double-blind, placebo-controlled, stratified, ascending dose, single center study, in three semi-sequential cohorts of 10 male and female subjects of nonchildbearing potential with Osteoarthritis (OA), administered GLPG1972 or placebo.
Per cohort, 10 subjects will be randomized in a 4:1 allocation ratio to active treatment with GLPG1972 or matching placebo.
In each cohort, OA subjects will be stratified for age (50- 64 years and 65-75 years) with a minimum of 2 of each sex per age group.
調査の概要
研究の種類
介入
入学 (実際)
30
段階
- フェーズ 1
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
Florida
-
Daytona Beach、Florida、アメリカ、32117
- Covance Daytona Beach
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
50年～75年 (大人、高齢者)
健康ボランティアの受け入れ
いいえ
受講資格のある性別
全て
説明
Inclusion Criteria:
- Male or female subjects of non-childbearing potential, 50-75 years of age on the date of signing the Informed Consent Form (ICF), inclusive extremes.
- Diagnosis of OA (knee and/or hip) made by their physician based on symptoms, clinical signs and documented historical imaging evidence.
- A body mass index (BMI) between 18.0 and 34.9 kg/m2, inclusive extremes.
- Judged to be in age-appropriate good health by the investigator based upon the results of a medical history, physical examination, vital signs and 12-lead ECG, and fasting clinical laboratory profile.
- Subjects with a stable chronic illness at least 3 months will be accepted subject to the investigator's judgment.
Exclusion Criteria:
- Administration of intraarticular glucocorticoid injections or hyaluronan injections in the last 3 months prior to study screening.
- Subjects who underwent or are on a waiting list for total hip or knee replacement and any other surgery planned during the study (up to Day 50).
- Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization.
- Positive serology for HBsAg or HCV antibody or history of hepatitis from any cause with the exception of hepatitis A.
- History of or a current immunosuppressive condition.
- Clinically significant serious, per investigator's discretion, and/or unstable illness in the 3 months before screening
- Renal function with an estimated creatinine clearance < 60 mL/min based on the Cockcroft-Gault formula. Retesting is allowed once (see Section 5.2).
- Use of verapamil, diltiazem, amitriptyline, warfarin, acenocoumarol, phenobarbital and phenytoin, within 4 weeks before first study drug administration
- Consumption of herbal medications that are strong inhibitors and/or inducers of CYPs (e.g., St. John's Wort) and grapefruit/grapefruit products, Seville oranges, or any poppy seed, within 7 days prior to the first study drug administration.
- History of solid organ or hematopoietic cell transplantation.
- History of malignancy within the past 5 years.
- Clinically significant abnormalities detected on 12-lead ECG of either rhythm or conduction (e.g., QTcF ≥ 450 ms for males and QTcF ≥ 470 ms for females, or a known long QT syndrome).
- Significant blood loss (including blood donation [> 450 mL]), or transfusion of any blood product within 12 weeks prior to screening
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター：プラセボ
|
Matching placebo provided as oral tablets q.d.
|
|
実験的：GLPG1972
|
GLPG1972 dose 1 provided as oral tablets q.d.
GLPG1972 dose 2 provided as oral tablets q.d.
GLPG1972 dose 3 provided as oral tablets q.d.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Difference between GLPG1972 treated subjects and placebo subjects in the number of Adverse Events
時間枠：From screening until the final follow up visit (day 50)
|
To assess safety and tolerability of GLPG1972 in OA patients
|
From screening until the final follow up visit (day 50)
|
|
Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal vital signs
時間枠：From screening until the final follow up visit (day 50)
|
To assess safety and tolerability of GLPG1972 in OA patients
|
From screening until the final follow up visit (day 50)
|
|
Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal clinical laboratory evaluations
時間枠：Screening, Days -1, 2, 4, 8, 9, 15, 22, 29, 43 and the final follow up visit (day 50)
|
To assess safety and tolerability of GLPG1972 in OA patients
|
Screening, Days -1, 2, 4, 8, 9, 15, 22, 29, 43 and the final follow up visit (day 50)
|
|
Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal physical examination
時間枠：Screening, days -1, 1, 2, 8, 15, 22, 29, 43 and the final follow up visit (day 50
|
To assess safety and tolerability of GLPG1972 in OA patients
|
Screening, days -1, 1, 2, 8, 15, 22, 29, 43 and the final follow up visit (day 50
|
|
Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal ECG
時間枠：Screening, days 1, 2, 3, 4, 8, 15, 22, 29, 43 and the final follow up visit (day 50)
|
To assess safety and tolerability of GLPG1972 in OA patients
|
Screening, days 1, 2, 3, 4, 8, 15, 22, 29, 43 and the final follow up visit (day 50)
|
|
Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal Holter assessment
時間枠：Day -1 to days 1 and Day 10 to day 11
|
To assess safety and tolerability of GLPG1972 in OA patients
|
Day -1 to days 1 and Day 10 to day 11
|
|
The maximum observed plasma concentration of GLPG1972 (Cmax)
時間枠：Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
|
To assess PK of GLPG1972 in OA patients
|
Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
|
|
The time (tmax) to reach Cmax of GLPG1972
時間枠：Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
|
To assess PK of GLPG1972 in OA patients
|
Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
|
|
The plasma concentration of GLPG1972 24 after the last dose
時間枠：Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
|
To assess PK of GLPG1972 in OA patients
|
Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
|
|
The area under the plasma concentration time curve from time 0 until the last quantifieble dose
時間枠：Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
|
To assess PK of GLPG1972 in OA patients
|
Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage reduction of neo-epitope ARGS vs baseline
時間枠：Days 1, 3, 6, 8, 10, 15, 22, 29, 43 and the final follow up visit (day 50)
|
To assess PD of GLPE1972 in OA patients
|
Days 1, 3, 6, 8, 10, 15, 22, 29, 43 and the final follow up visit (day 50)
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
捜査官
- スタディディレクター：Ann Fieuw, MD, MSc、Galapagos NV
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2017年5月15日
一次修了 (実際)
2017年10月25日
研究の完了 (実際)
2017年10月25日
試験登録日
最初に提出
2017年10月11日
QC基準を満たした最初の提出物
2017年10月11日
最初の投稿 (実際)
2017年10月16日
学習記録の更新
投稿された最後の更新 (実際)
2017年11月24日
QC基準を満たした最後の更新が送信されました
2017年11月21日
最終確認日
2017年11月1日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。